MedTrace Logo

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

NCT06182774 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2026-05-12

No results posted yet for this study

Summary

Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?

Conditions

Interventions

DRUG

Daratumumab

Dose determined at enrollment

DRUG

Lenalidomide

Dose determined at enrollment

DRUG

Dexamethasone

Dose determined at enrollment

DRUG

Isatuximab

Dose determined at enrollment

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Myeloma Canada

    collaborator UNKNOWN

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Hira Mian · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2032-01-31
Completion
2032-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06182774 on ClinicalTrials.gov